Fig. 5.
TMEM16A-specific blockade via functional antibody treatment corroborates pharmacological TMEM16A antagonist effects on STICs. A and B: representative whole cell recordings of STICs in immortalized human airway smooth muscle cells following incubation with vehicle (A) or TMEM16A antibody (B). C and D: antibody-mediated blockade of TMEM16A led to a functional loss of STIC amplitude and frequency compared with vehicle-treated cells (*P < 0.05, and *P < 0.05, respectively).
